$CDXS

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

Original reporting
Published Jul 23, 2026, 8:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CDXS
Neutral
medium confidence
Mentioned
$CDXS
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDXSNeutralMed
01

Why it matters

The disclosure sets a near-term reference point for revenue and liquidity, which can affect expectations for profitability trajectory and runway until the final quarter results are published.

02

Market read

Traders can use the preliminary revenue and cash figures to update short-term expectations and position for potential confirmation or revision risk into the final earnings release.

03

What to watch

Watch for the magnitude of any gap between these preliminary numbers and the final reported results, plus any commentary in the eventual 10-Q that could reframe revenue quality or cash burn.

Relevance 7/10Novelty 7/10Timing: after-hours, ahead of the final Q2 financial statements for the quarter ended June 30, 2026

Background

The company filed an SEC Form 8-K under Item 2.02 providing preliminary financial estimates for the three months ended June 30, 2026.

Company-level read

Ticker impact

$CDXSNeutralMedium confidence
Context

Codexis (CDXS) pre-announces Q2 ended June 30, 2026 revenue of at least $14.8M and cash plus short-term investments of about $54.9M.

Expected impact

Likely modest volatility into the final earnings release, with direction dependent on whether the eventual reported numbers confirm or diverge from these preliminary figures.

Evidence & confidence

The filing is a primary-source 8-K with specific preliminary metrics, but it is explicitly unaudited and subject to change after closing procedures and management review.

Market effects

Limited read-across; this is company-specific liquidity and revenue guidance rather than a sector-wide datapoint.

Minimal, as the disclosure is specific to a US-listed microcap and does not indicate broader regional demand or funding conditions.

Low; no international counterparties or global macro drivers are disclosed.

Counterpoint

Because the figures are preliminary and explicitly unaudited, the market may discount them and focus on the eventual finalized earnings and any updated outlook rather than trading the estimate itself.

Key entities

  • Codexis, Inc.

    US-listed issuer (CDXS) providing preliminary Q2 revenue and cash plus short-term investments estimates in an 8-K.

  • Georgia Erbez

    CFO and Chief Business Officer signing the 8-K.

Related articles

$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

$EQIXMedAI 8/10

Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here

Equinix (EQIX) reported Q2 revenue of $2.63B, up 16% YoY, beating estimates. AFFO was $11.78/share, up 19% YoY. The company raised full-year guidance and unveiled a multi-year growth plan. EQIX stock has surged 34% over the past year and offers a 1.98% dividend yield. Analysts rate it a 'Strong Buy' with an average price target of $1,232.19.

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.